Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GOLD study of glofitamab after CAR T-cell failure in mantle cell lymphoma
2025-523428-39-00Phase 2Authorised
- Sponsor
- Fondazione Italiana Linfomi
- Start
- Jun 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of glofitamab in mantle cell lymphoma (MCL), sponsored by Fondazione Italiana Linfomi. Primary endpoint: Complete response rate at any time during study treatment. Planned start Jun 2026; status: authorised.
02
Drugs
glofitamab
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2025-523428-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523428-39-00.